Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced a conference call on May 11, 2020, at 4:30 p.m. ET to discuss Q1 2020 financial results and provide a corporate update. The company focuses on developing treatments that alleviate pruritus by targeting peripheral kappa opioid receptors. Its lead candidate, KORSUVA™ (CR845/difelikefalin), has shown significant efficacy in Phase 3 trials for patients with chronic kidney disease-associated pruritus. The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection.

Positive

• KORSUVA demonstrated statistically significant reductions in itch intensity and improved quality of life in Phase 3 trials.
• Oral KORSUVA is in Phase 2 trials, expanding treatment capabilities for various pruritic conditions.

Negative

• None.

STAMFORD, Conn., May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020, at 4:30 p.m. ET to report first quarter 2020 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 3875739. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis (PBC).

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
Jane.Urheim@SternIR.com

FAQ

What are the financial results for Cara Therapeutics for Q1 2020?

Cara Therapeutics will report its Q1 2020 financial results during the conference call on May 11, 2020.

What is KORSUVA and its significance to Cara Therapeutics?

KORSUVA is a first-in-class kappa opioid receptor agonist developed by Cara Therapeutics, demonstrating significant efficacy in treating pruritus in clinical trials.

When will the conference call for Cara Therapeutics take place?

The conference call will be held on May 11, 2020, at 4:30 p.m. ET.

How can I access the live webcast of the Cara Therapeutics conference?

The live webcast can be accessed on the Cara Therapeutics website under the 'Events & Presentations' section.

What is the status of KORSUVA's regulatory approval?

The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection, but its safety and efficacy are still under evaluation.